Dr Reddys Laboratories, an integrated global pharmaceutical company, gained on Wednesday after it launched Paricalcitol Capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent generic version of Zemplar (Paricalcitol) Capsules in the US market, following the approval by the United States Food & Drug Administration (USFDA).

The Zemplar brand and generic had US sales of approximately USD 109.6 million MAT for the most recent twelve months ending in March 2014 according to IMS Health.

Shares of the company are trading at Rs 2,464.80, up Rs  3.95 or 0.16% at the Bombay Stock Exchange (BSE) on Wednesday at 12:25 p.m.

The scrip has touched an intra-day high of Rs 2,470.80 and low of Rs 2,453.70. The total volume of shares traded at the BSE is 3,373.